Search alternatives:
teer decrease » greater decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), use decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
teer decrease » greater decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), use decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
4581
-
4582
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
-
4583
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
-
4584
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
-
4585
-
4586
-
4587
Heterogeneity analysis.
Published 2025“…Instrumental variables (IVs) were identified as genome-wide significant single-nucleotide polymorphisms (SNPs) with a significance threshold of <i>P </i>< 1 × 10<sup>−8</sup> and an independence criterion of <i>r</i><sup>2</sup> < 0.001. …”
-
4588
Reverse MR analysis data.
Published 2025“…Instrumental variables (IVs) were identified as genome-wide significant single-nucleotide polymorphisms (SNPs) with a significance threshold of <i>P </i>< 1 × 10<sup>−8</sup> and an independence criterion of <i>r</i><sup>2</sup> < 0.001. …”
-
4589
SNP dressing by screening.
Published 2025“…Instrumental variables (IVs) were identified as genome-wide significant single-nucleotide polymorphisms (SNPs) with a significance threshold of <i>P </i>< 1 × 10<sup>−8</sup> and an independence criterion of <i>r</i><sup>2</sup> < 0.001. …”
-
4590
-
4591
-
4592
-
4593
-
4594
Effect of O-ag modifying glycosyltransferases on complement activation and <i>Salmonella</i> interactions with human serum.
Published 2025“…</i> Paratyphi A decrease complement activation as measured by C5a release and (B) IgM binding. …”
-
4595
Reduction of L O-ag production and antigenic shift to O2-antigen in
Published 2025“…<p><b><i>S.</i> Paratyphi A decreases IgM binding. (</b>A) and (B) Restored <i>S.…”
-
4596
Continuing evolution of H5N1 highly pathogenic avian influenza viruses of clade 2.3.2.1a G2 genotype in domestic poultry of Bangladesh during 2018–2021
Published 2024“…Consequently, antigenic analysis revealed a significant loss of cross-reactivity between viruses from different host species and periods. …”
-
4597
-
4598
-
4599
-
4600